These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12086588)

  • 1. Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion.
    Bertuglia S; Giusti A
    BMC Cardiovasc Disord; 2002 Jun; 2():10. PubMed ID: 12086588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
    J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab.
    Speich HE; Earhart AD; Hill SN; Cholera S; Kueter TJ; Smith JN; White MM; Jennings LK
    J Thromb Haemost; 2009 Jun; 7(6):983-91. PubMed ID: 19548907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
    Moser M; Bertram U; Peter K; Bode C; Ruef J
    J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ
    J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G
    J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury.
    Kupatt C; Habazettl H; Hanusch P; Wichels R; Hahnel D; Becker BF; Boekstegers P
    Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):2226-32. PubMed ID: 11031208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
    Frelinger AL; Furman MI; Barnard MR; Krueger LA; Dae MW; Michelson AD
    Am J Cardiol; 2003 Nov; 92(9):1099-101. PubMed ID: 14583364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro effects of the glycoprotein IIb/IIIa receptor antagonists abciximab and eptifibatide on platelet aggregation in healthy cats.
    Magee AN; Hogan DF; Sederquist KA; Durham JA
    Am J Vet Res; 2014 Mar; 75(3):309-12. PubMed ID: 24564318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preservation of myocardial microcirculation during mechanical reperfusion for myocardial ischemia with either abciximab or eptifibatide.
    Stoupakis G; Orlando J; Kalia H; Skurnick J; Saric M; Arora R
    J Invasive Cardiol; 2003 Sep; 15(9):476-80. PubMed ID: 12947204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease.
    Amoroso G; van Boven AJ; van Veldhuisen DJ; Tio RA; Baljé-Volkers CP; Petronio AS; van Oeveren W
    J Cardiovasc Pharmacol; 2001 Oct; 38(4):633-41. PubMed ID: 11588534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
    Lev EI; Osende JI; Richard MF; Robbins JA; Delfin JA; Rodriguez O; Sharma SK; Jayasundera T; Badimon JJ; Marmur JD
    J Am Coll Cardiol; 2001 Mar; 37(3):847-55. PubMed ID: 11693761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA
    J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
    Harder S; Klinkhardt U; Graff J; Westrup D; Kirchmaier CM; Glusa E; Mascelli MA; Marciniak SJ; Just A; Lösche W; Breddin HK
    Thromb Res; 2001 Apr; 102(1):39-48. PubMed ID: 11323013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.
    Speich HE; Furman RR; Lands LT; Moodie GD; Jennings LK
    J Thromb Thrombolysis; 2013 Jul; 36(1):31-41. PubMed ID: 23073747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
    Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic cerebral capillary blood flow improvement after deep hypothermic circulatory arrest: an intravital fluorescence microscopy study in pigs.
    Ben Mime L; Arnhold S; Fischer JH; Addicks K; Rainer de Vivie E; Bennink G; Suedkamp M
    J Thorac Cardiovasc Surg; 2005 Sep; 130(3):670-6. PubMed ID: 16153911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet glycoprotein IIb/IIIa receptor antagonist (abciximab) inhibited platelet activation and promoted skin flap survival after ischemia/reperfusion injury.
    Kuo YR; Jeng SF; Wang FS; Huang HC; Wei FC; Yang KD
    J Surg Res; 2002 Sep; 107(1):50-5. PubMed ID: 12384064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.